• First commercially available, fully defined serum-free media for immunological studies
  • Lot-to-lot consistency and produced under cGMP

Superior performance, no serum required

Gibco AIM V Medium does not require human serum for optimal growth and activation of differentiated lymphoid cells.

  • Minimizes risk of viral immunogenicity associated with human serum
  • Contains no added cytokines and lymphokines
  • All proteins in the formulation have the natural human sequence

AIM V versus human serum–supplemented medium

Figure 1 compares relative LAK cell lytic activity of lymphocytes maintained in AIM V Medium with lymphocytes maintained in RPMI-1640 supplemented with serum.

      Figure 1. Comparison of LAK cell lytic activity: AIM V Medium versus human serum–supplemented medium. Human peripheral blood lymphocytes (PBLs) were cultured in RPMI-1640 with 1,000 units/mL of IL-2 plus 2% human serum type AB. Human PBLs were also cultured in serum-free AIM V Medium with 600 units/mL of IL-2. Results are expressed as averages of duplicate flasks assayed in triplicate using Daudi cells as targets.

Applications of AIM V Medium

AIM V Medium has been tested for broad range of applications in adoptive immunotherapy and cellular immunology research. See some of the applications here:

LAK cell induction & functionCytokine & antibody effects on LAK cell induction
Immunotherapy of murine hepatic metastasesLymphocyte receptor studies
TIL cell generation in hollow fiber bioreactorsNK cells & NK-like effector populations
T cell activationIn vitro & in vivo model systems for adoptive immunotherapy
Cytokine regulation of effector cellsHIV research
Cytokine receptor & postreceptor events in lymphoid effector cellsMacrophage activation
Hybridoma growth & monoclonal antibody productionAntibody-dependent cellular cytotoxicity
Effector cells in antitumor immunityLong-term cultivation of functional human macrophages
In vitro studies of lymphokines & antibodiesMechanisms of cell-mediated cytotoxicity

Cells types grown using AIM V Medium

T cell types

  • CD8+ T lymphocytes
  • Polyclonal T cells
  • Peripheral blood lymphocytes (PBL)
  • CD4 cells for HIV patients
  • Tumor infiltrating lymphocytes (TIL)
  • Retroviral transduced PBL
  • CD3 positive NK T cells
  • Antigen-specific cells (not clonal)
  • γδ T cells
  • NK cells

Other cell types

  • Macrophages
  • Human monocytes
  • HUT78 (human)
  • Dendritic cells
  • HL-60
  • COS cells (monkey)
  • YAC-1 (mouse)
  • Murine lymphoma
  • Myeloid cells
  • Leukemic cells
  • Human fibroblasts
  • VERO
  • Oral epithelial
  1. Dietze B., et al. (2008) An improved method to generate equine dendritic cells from peripheral blood mononuclear cells: divergent maturation programs by IL-4 and LPS. Immunobiology 213:751–758.
  2. Meehan K.R., et al. (2008) Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy 10: 30–37.
  3. Ye Z., et al. (2006) Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity. Cancer Biother Radiopharm 21:613–622.
  4. Choi B.H., et al. (2006) Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy. J Clin Apher 21: 233–240.
  5. Imataki O., et al. (2006) Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells. J Immunother 29: 320–327. 
  6. Peng J.C., et al. (2005) Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 28: 599–609.
  7. Trickett A.E., et al. (2002) Ex vivo expansion of functional T lymphocytes from HIV-infected individuals. J Immunol Methods 262: 71–83.
  8. Carlens S., et al. (2000) Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. Exp Hematol 28: 1137–1146.
  9. Kambe N et al. (2000) An improved procedure for the development of human mast cells from dispersed fetal liver cells in serum-free culture medium. J Immunol Methods 240: 101–110.
  10. Gerin P.A., et al. (1999) Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol Prog 15: 941–948. 
  11. Slunt J.B., et al. (1997) Human T-cell responses to Trichophyton tonsurans: inhibition using the serum free medium Aim V. Clin Exp Allergy 27: 1184–1192.
  12. Kreuzfelder E., (1996) Assessment of peripheral blood mononuclear cell proliferation by [2-3H]adenine uptake in the woodchuck model. Clin Immunol Immunopathol 78: 223–227.
  13. Causey A.L., (1994) A serum-free medium for human primary T lymphocyte culture. J Immunol Methods 175: 115–121.
  14. Freedman R.S., et al. (1994) Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 167: 145–160.
  15. Nomura K., et al. (1993) [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation] Nippon Hinyokika Gakkai Zasshi 84: 831–840. Japanese.
  16. Kaldjian E.P., et al. (1992) Enhancement of lymphocyte proliferation assays by use of serum-free medium. J Immunol Methods 147: 189–195.
  17. Hayakawa K., et al. (1991) Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother 10: 313–325.
  18. McVicar D.W., et al. (1991) A comparison of serum-free media for the support of in vitro mitogen-induced blastogenic expansion of cytolytic lymphocytes. Cytotechnology 6: 105–113.
  19. Burg S., et al. (1991) [Effect of different media on long-term cultivation of human synovial macrophages] Z Rheumatol 50: 142–150. German.
  20. Helinski E.H., et al. (1988) Long-term cultivation of functional human macrophages in Teflon dishes with serum-free media. J Leukoc Biol 44: 111–121.
  21. Robyn S., et al. (2007) RA8, A Human Anti-CD25 Antibody Against Human Treg Cells Hybridoma 26: 119–130.
  22. Chena X., et al.(2006) Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors Cellular Immunology 243: 10–18.
  23. Grant R., et al. (2008) CCL2 Increases X4-tropic HIV-1 Entry into Resting CD4+ T Cells. J Biol Chem 283: 30745–30753.
  24. Hagihara M., et al. (2003) Increased frequency of CD3/8/56-positive umbilical cord blood T lymphocytes after allo-priming in vitro Annals of Hematology 82: 166–170.
  25. Wang, Z., et al. (2006) Application of Serum-Free Culture Medium for Preparation of A-NK Cells Cell Mol Immunol 3: 391–395.
  26. Morecki S., et al. (1991) Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells Cancer Immunol Immunotherapy 32: 342–352.
  27. Johansen P. et al. Cellular immune response—CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells Eur J Immunol 34: 91–97.

Additional AIM-V medium references

  1. Rebecca J et al., (2010) Natural exposure to cutaneous anthrax gives long lasting T cell immunity encompassing infection-specific Epitopes. J. Immunol.,  2010; 184: 3814 – 3821
  2. Fabricius D et al., (2010) Prostaglandin E2 inhibits IFN-α secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J. Immunol., 2010; 184: 677 - 684.
  3. Jahrsdorfer B et al., Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood, 2010; 115: 1156 - 1165.
  4. Tam V et al., The RgpA-Kgp Proteinase-Adhesin Complexes of Porphyromonas gingivalis Inactivate the Th2 Cytokines Interleukin-4 and Interleukin-5. Infect. Immun., 2009; 77: 1451 - 1458.
  5. Ando T et al., Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress J. Immunol., 2008; 181: 8382 - 8390.
  6. Nesbit L et al., Polyfunctional T Lymphocytes Are in the Peripheral Blood of Donors Naturally Immune to Coccidioidomycosis and Are Not Induced by Dendritic Cells. Infect. Immun., 2010; 78: 309 - 315.
  7. Csillag A et al., Pollen-Induced Oxidative Stress Influences Both Innate and Adaptive Immune Responses via Altering Dendritic Cell Functions. J. Immunol., 2010; 184: 2377 - 2385.
  8. Bellone S et al., Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines. J. Virol., 2009; 83: 6779 - 6789.
  9. Liu ZW et al., A CD26-Controlled Cell Surface Cascade for Regulation of T Cell Motility and Chemokine Signals. J. Immunol., 2009; 183: 3616 - 3624.
  10. Megyeri M et al., Complement Protease MASP-1 Activates Human Endothelial Cells: PAR4 Activation Is a Link between Complement and Endothelial Function. J. Immunol., 2009; 183: 3409 - 3416.
  11. Asish K. et al., Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG. Clin. Cancer Res., 2009; 15: 1250 -1258
  12. Cornberg M et al., CD8 T Cell Cross-Reactivity Networks Mediate Heterologous Immunity in Human EBV and Murine Vaccinia Virus Infections. J. Immunol., 2010; 184: 2825 - 2838.
  13. Ariadne L et al., The Gli3 Transcription Factor Expressed in the Thymus Stroma Controls Thymocyte Negative Selection Via Hedgehog-Dependent and -Independent Mechanisms. J. Immunol., 2009; 183: 3023 - 3032.
  14. Hagn M et al., Human B Cells Secrete Granzyme B When Recognizing Viral Antigens in the Context of the Acute Phase Cytokine IL-21. J. Immunol., 2009; 183: 1838 - 1845.
  15. Lenka L et al., Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood, 2009; 114: 2411 - 2416.
  16. Toll-like Receptor-7 Tolerizes Malignant B Cells and Enhances Killing by Cytotoxic Agents. Cancer Res., 2007; 67: 1823 - 1831.
  17. Andrei V et al.,  Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor  B target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood, 2007; 110: 735 - 742.
  18. Caitlin M et al.,   Extracellular calcium sensing promotes human B-cell activation and function. Blood, 2007; 110: 3985 - 3995.

AIM V medium is widely used on T cells, T cell lines, lymph node cells and dendritic cells.

  • HUVEC cells is reported to culture in AIM V with 1% FBS and growth factors (reference 10)
  • CLL B cell (reference 11, 17)
  • CLL cells (reference 16)
  • Fetal thymus (reference 13)
  • Human B cells (reference 14, 15, 18)